🔎 Trials Near Me

Beranda › Limfoma Burkitt › Nevada

Uji klinis Limfoma Burkitt di Nevada

6 studi untuk Limfoma Burkitt mencari peserta di lokasi di Nevada.

Kota di Nevada

Teks studi resmi (Bahasa Inggris)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • OptumCare Cancer Care at Charleston, Las Vegas
  • OptumCare Cancer Care at Fort Apache, Las Vegas
Menerima pesertaFase 3
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • OptumCare Cancer Care at Charleston, Las Vegas
  • OptumCare Cancer Care at Fort Apache, Las Vegas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
  • Summerlin Hospital Medical Center, Las Vegas
  • Renown Regional Medical Center, Reno
Menerima pesertaFase 2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
  • Summerlin Hospital Medical Center, Las Vegas
  • Renown Regional Medical Center, Reno
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.